Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Embodied Innovation And Regulation Of Medical Technoscience: Transformations In Cancer Patienthood

A. Kerr, S. Cunningham-Burley
Published 2015 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
ABSTRACT Biomedical advances are transforming the diagnosis and treatment of disease. Patienthood is also transforming, as patients actively participate in research, innovation and regulation of novel technologies and therapies. In this paper we explore the new kinds of practices that patients are performing in their roles as research subject, co-researchers, donors, campaigners, representatives and consumers of novel stratified therapies. We outline their embodied contributions to clinical trials, biobanks and stratified therapies prior to, during and after having cancer. Exploring how patienthood involves donating more than tissue or data to these developments, we consider their emotional and identity work which informs and shapes the novel diagnostics and therapies being developed. We also consider how this kind of work is stratified according to the social and biological location of participants, and end by reflecting on the implications of our analysis for the organisation and regulation of biomedicine.
This paper references
Author manuscript; available in PMC
Innov Law (2016)
Personalized Therapies in the Cancer
Alberto Ocana (2010)
Did Nice listen to cancer patients when they rejected Abiraterone and Kadycla? The Telegraph
Judith Potts
10.4324/9780203884607
Human Genetic Biobanks in Asia : Politics of trust and scientific advancement
M. Sleeboom-Faulkner (2009)
10.5860/choice.47-1460
When Experiments Travel: Clinical Trials and the Global Search for Human Subjects
A. Petryna (2009)
10.2307/2578990
The Managed Heart: Commercialization of Human Feeling.
J. V. Brown (1985)
10.1136/jme.2010.035485
What do our patients understand about their trial participation? Assessing patients' understanding of their informed consent consultation about randomised clinical trials
C. Behrendt (2010)
10.1016/J.SOCSCIMED.2005.06.023
Introduction: Patient organization movements and new metamorphoses in patienthood.
Kyra Landzelius (2006)
10.1177/0018726714525975
‘Why would you want to do that?’: Defining emotional dirty work
R. McMurray (2014)
10.1377/hlthaff.2011.1300
How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies.
D. Lakdawalla (2012)
10.1038/nrc2913
Integrating biobanks: addressing the practical and ethical issues to deliver a valuable tool for cancer research
R. Watson (2010)
10.1080/13698575.2013.830081
Considering a future which may not exist: the construction of time and expectations amidst advanced-stage cancer
Patrick Brown (2013)
10.7208/chicago/9780226428932.001.0001
Cancer on Trial: Oncology as a New Style of Practice
P. Keating (2011)
10.1038/nm0297-242
Impure Science: AIDS, Activism, and the Politics of Knowledge
S. Epstein (1997)
10.1038/sj.bjc.6604571
Cancer survival in England and Wales at the end of the 20th century
B. Rachet (2008)
10.4324/9780203567234-13
PERFORMATIVE ACTS AND GENDER CONSTITUTION: AN ESSAY IN PHENOMENOLOGY AND FEMINIST THEORY
J. Butler (1988)
10.2307/2092457
The phenomenology of the social world
A. Schutz (1967)
Integrate rail: why would you want to do that?
M. Carter (2004)
10.1038/bjc.2011.250
What is the lifetime risk of developing cancer?: the effect of adjusting for multiple primaries
P. Sasieni (2011)
10.1108/RR-06-2014-0167
The Wiley-Blackwell Encyclopedia of Health, Illness, Behavior and Society
M. Guha (2014)
Improving the Patient Experience of Clinical Trials Apr 17. www.lilly.co.uk/global/img
Eli Lilly (2014)
Ethics left behind as drug trials soar in developing countries
Scidev Net
10.1080/03085140050174750
Genetic risk and the birth of the somatic individual
C. Novas (2000)
46. www.biobank.org (accessed 27
(2015)
10.1016/j.socscimed.2012.04.022
"They should take time": disclosure of clinical trial results as part of a social relationship.
A. Sarradon-Eck (2012)
10.20529/ijme.2014.044
US-funded measurements of cervical cancer death rates in India: scientific and ethical concerns.
E. Suba (2014)
10.1111/j.1468-2230.2005.557_5.x
Genetic Databases: Socio-Ethical Issues in the Collection and Use of DNA
J. Gillott (2005)
10.1002/embr.201438641
Key challenges for next‐generation pharmacogenomics
Kostas Kampourakis (2014)
Hochschild, Arlie. The Managed Heart: Commercialization of Human Feeling University of California Press2012
See James
Department of Health. [accessed 26 January 2015] www.genomicsengland.co.uk/about-genomics-england/how-we-work 37
10.2307/1519765
Biomedicalization: Technoscientific Transformations of Health, Illness, and U.S. Biomedicine
A. Clarke (2003)
10.5661/bger-25-429
The Ethics of Research Biobanking: A Critical Review of the Literature
K. Hoeyer (2008)
Ribbon Blues: How Breast Cancer Culture Undermines Women’s Health
Sulik (2010)
10.1038/ejhg.2014.71
Dynamic consent: a patient interface for twenty-first century research networks
J. Kaye (2015)
10.1111/j.1467-9566.2009.01183.x
Managing biomedical uncertainty: the technoscientific illness identity.
Gayle A. Sulik (2009)
10.1136/bmj.g5078
NICE confirms advanced breast cancer drug is too expensive for NHS
C. White (2014)
10.2307/3324333
The Managed Heart: Commercialization of Human Feeling
J. Tropman (1984)
10.1159/000151365
Participation in Clinical Trials as Viewed by the Patient: Understanding Cultural and Emotional Aspects Which Influence Choice
C. Catania (2008)
10.1177/136345930200600304
Stem Cells, Tissue Cultures and the Production of Biovalue
Catherine Waldby (2002)
The Guardian. London: 2011 Jul 4. Ethics left behind as drug trials soar in developing countries
SciDev Net (2014)
Callon, Michel; Rabeharisoa, Vololona. The Growing Engagement of Emergent Concerned Groups in Political and Economic Life: Lessons from the French Association of Neuromuscular Disease Patients
Steven Epstein (1996)
The Guardian. London: 2011 Jul 4 Ethics left behind as drug trials soar in developing countries. www.theguardian.com/global-development/2011/jul/04/ethics-left-behind-drug-trials- developing
Scidev Net (2014)
Rose, Nikolas; Novas, Carlos. Biological Citizenship. Global Assemblages: Technology, Politics, and Ethics as Anthropological Problems Added Value? Doing Research in the National Health Service
(2006)
10.1016/J.JCPO.2013.11.001
Affordability of cancer care in the United Kingdom - Is it time to introduce user charges?
Ajay Aggarwal (2014)
Patient Stories Patients share their experiences with participating in clinical trials
10.1186/1745-6215-15-126
Disappointment and adherence among parents of newborns allocated to the control group: a qualitative study of a randomized clinical trial
Sandra Meinich Petersen (2014)
10.5749/j.cttts72q.17
Department of Health.
J. B. Gregg (1983)
10.1016/S0277-9536(01)00197-6
"Why don't they just tell me straight, why allocate it?" The struggle to make sense of participating in a randomised controlled trial.
Katie Featherstone (2002)
10.1016/j.socscimed.2009.03.034
Why do people cooperate with medical research? Findings from three studies.
M. Dixon-Woods (2009)
10.1177/0162243907311264
The Growing Engagement of Emergent Concerned Groups in Political and Economic Life
M. Callon (2008)
10.1016/J.PUHE.2011.09.017
Medical Proofs, Social Experiments: Clinical Trials in Shifting Contexts
I. Harvey (2012)
Human Genetic Biobanks in Asia
Margaret Sleeboom-Faulkner (2009)
Europe PMC Funders Author Manuscripts Europe PMC Funders Author Manuscripts
10.1057/biosoc.2013.6
Biomarkers, the molecular gaze and the transformation of cancer survivorship
Kirsten Bell (2013)
10.5324/NJE.V21I2.1496
Size matters: the ethical, legal, and social issues surrounding large-scale genetic biobank initiatives
K. Hoeyer (2012)
10.1111/1467-9566.12094
Careful science? Bodywork and care practices in randomised clinical trials.
A. Jespersen (2014)
10.1371/journal.pmed.1000376
Participatory Epidemiology: Use of Mobile Phones for Community-Based Health Reporting
C. Freifeld (2010)
10.1056/NEJMp0911494
The missing voice of patients in drug-safety reporting.
E. Basch (2010)
10.1111/1467-9566.12092
Therapeutic journeys: the hopeful travails of stem cell tourists.
A. Petersen (2014)
10.1215/18752160-3483343
Clinical Labor: Tissue Donors and Research Subjects in the Global Bioeconomy
Heong Hong Por (2016)
10.1046/J.1365-2354.2002.00341.X
Capturing users' experiences of participating in cancer trials.
J. Donovan (2002)
10.1016/j.cct.2009.09.003
Disappointment and drop-out rate after being allocated to control group in a smoking cessation trial.
D. Lindström (2010)
10.1016/j.nbt.2012.03.004
A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory.
Leroy E Hood (2012)
Improving the Patient Experience of Clinical Trials
Eli Lilly (2014)
Author manuscript; available in PMC
Law Innov Technol
The Cancer Drugs Fund Benign or malignant? A well-meaning gesture is causing more and more trouble
10.1111/j.1467-9566.2010.01310.x
Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation.
Courtney Davis (2011)
10.1177/0306312710385852
Generating sociability to drive science: Patient advocacy organizations and genetics research
A. Panofsky (2011)
10.1111/j.1467-9566.2011.01348.x
Enterprising or altruistic selves? Making up research subjects in genetics research.
R. Tutton (2011)
10.1016/0277-9536(94)90017-5
Interrogating the Human Diversity Genome Project.
M. Lock (1994)
10.1200/JCO.2010.33.2668
Supporting clinical practice decisions with real-time patient-reported outcomes.
Ethan Basch (2011)
Key Challenges for NextGeneration Pharmacogenomics
Kostas Kampourakis (2014)
10.1200/JCO.1995.13.5.1062
Perceptions of cancer patients and their physicians involved in phase I trials.
C. Daugherty (1995)
A Phenomenology of the Social World. Heinemann Educational Books
Alfred Schutz (1972)
NICE rejects 'costly' cancer treatment for NHS use' National Health Executive
Anon
10.32388/pfg7jq
International agency for research on cancer.
J. Higginson (1974)
10.1146/annurev-genom-090711-163834
Sampling populations of humans across the world: ELSI issues.
B. Knoppers (2012)
10.1002/hast.65
Personalized genomic medicine and the rhetoric of empowerment.
E. Juengst (2012)
10.1080/03085149300000018
Liberal government and techniques of the self
Graham D. Burchell (1993)
Is Nice shirking its duty of care by blocking the Abiraterone prostate cancer therapy? The Telegraph
See Potts (2012)
10.1046/J.1467-9566.2003.00369.X
Empty ethics: the problem with informed consent.
O. Corrigan (2003)
10.1186/1745-6215-15-323
Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences
N. Mills (2014)
Novas, Carlos. The Political Economy of Hope: Patients' Organizations
Catherine Waldby (2002)
10.1016/j.shpsc.2011.05.001
'Population laboratories' or 'laboratory populations'? Making sense of the Baltimore Longitudinal Study of Aging, 1965-1987.
Tiago Moreira (2011)
10.5860/choice.43-2283
Global assemblages : technology, politics, and ethics as anthropological problems
A. Ong (2005)
10.1111/J.1467-9566.2011.01417.X
Pink Ribbon Blues: How Breast Cancer Culture Undermines Women’s Health
Sukari Ivester (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar